Navigation Links
Women with HIV shown to have elevated resting energy expenditure
Date:4/15/2013

Philadelphia, PA, April 16, 2013 Studies have shown that about 10 percent of men infected with human immunodeficiency virus (HIV) have an elevated resting energy expenditure (REE). Their bodies use more kilocalories for basic functions including circulation, body temperature, and breathing. Most studies have been conducted in men and those with solely women have had small sample sizes. A team of researchers has sought to rectify this with a matched, prospective, cross-sectional study. The results are featured in a new report published by the Journal of the Academy of Nutrition and Dietetics.

"To our knowledge, no studies have been conducted that dissect the effect of HIV infection versus antiretroviral therapy," says lead investigator Grace McComsey, MD, FIDSA, Chief Pediatric Infectious Diseases, Rheumatology and Global Health at Case Western Reserve University School of Medicine. "The purpose of our study was to compare REE in HIV-infected women who have never been on antiretroviral therapy (ART), those on ART with virologic suppression, those on ART with detectable HIV-1 RNA, and HIV-negative, healthy women." Antiretroviral therapy typically consists of at least three drugs to fight against fatal HIV effects and improve quality of life.

The study team recruited women from the John T. Carey Special Immunology Unit at University Hospitals Case Medical Center, an out-patient HIV clinic in Cleveland, Ohio between 2004 and 2011. The women were matched by age and body mass index (BMI). Healthy women who volunteered to participate in the control group were mostly hospital employees. In total, 87 women participated, 62 with HIV and 25 without.

All participants received a clinical evaluation for weight, height, and waist and hip measurements and responded to questions about their exercise habits and alcohol, tobacco, and drug use. Investigators determined their body composition and measured their oxygen consumption to determine REE
'/>"/>

Contact: Eileen Leahy
andjrnlmedia@elsevier.com
732-238-3628
Elsevier Health Sciences
Source:Eurekalert

Page: 1 2

Related biology news :

1. Inter-American Network of Science Academies celebrates women scientists -- April 17 event
2. Study reveals risk factors for blood clots in pregnant and postnatal women
3. Men and women get sick in different ways
4. European Guidance for the diagnosis & management of osteoporosis in postmenopausal women
5. Stereotyping prime obstacle to women in commercial science
6. New book celebrates women scientists in the Americas
7. Progesterone may be why pregnant women are more vulnerable to certain infections
8. Genetic signs of alcoholism in women studied for the first time
9. African-American, Caucasian women should take identical vitamin D doses
10. Cancer risk for African-American women with benign breast disease factors Wayne State finds
11. Few pregnant women treated for sexually transmitted infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014) Scientists at The New York Stem ... closer to creating a viable cell replacement therapy ... , For the first time, NYSCF scientists ... skin samples of patients with primary progressive multiple ... to induce these stem cells into becoming oligodendrocytes, ...
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... Hopkins scientists seems to have discovered an almost-too-easy way to ... potent versions. Their finding, reported this week in Nature, could ... but also other body tissues. What the researchers ... neural stem cells the sort that might be used ...
... The giant panda is not at an evolutionary dead end ... new research involving scientists from Cardiff University. Previous ... requirements and slow reproductive rates have led to a lack ... extinction. Now a study by Professor Michael Bruford ...
... August 23, 2007 On August 16, the Food and ... sold under the brand name Coumadin. The new label suggests ... be safer for patients with variations in two genes, CYP2C9 ... testing, which may be a useful tool in determining appropriate ...
Cached Biology News:When is a stem cell not really a stem cell? 2American College of Medical Genetics responds to new FDA labeling decision for warfarin 2
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Cell Culture Market 2014-2018" report ... Cell culture is the in vitro ... such as research, cell studies, and biopharmaceutical production. Cell ... vaccine production. Cell culture instruments and cell culture consumables ...
(Date:7/24/2014)... Your cell phone may stay charged ... storage capacity. , New research indicates that lithium-ion ... at Lawrence Livermore National Laboratory and ... components will perform as electrodes. , The growing ... for higher-performance batteries. Several key characteristics of lithium-ion ...
(Date:7/24/2014)...  CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical ... for the prevention and treatment of cardiorenal and ... July 18, 2014 from the NYSE MKT LLC ... plan to regain compliance with continued listing standards ... is continuing the Company,s listing and has granted ...
(Date:7/24/2014)... 2014 2014 Deep Research Report ... a professional and in-depth research report on Potassium ... basic information, including its definition, classification, application, ... research covers the international market analysis, including China’s ... covering macroeconomic environment & economic situation analysis, the ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2Getting More Life out of Lithium-ion Batteries 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4
... , , ROCKVILLE, Md., ... has announced that 263 regulatory professionals achieved Regulatory Affairs ... RAC credential is administered by RAPS and is the ... product sector. , , (Logo: ...
... BEIJING, Sept. 4 /PRNewswire-Asia/ -- ... provider of biopharmaceutical products in China, announced today that,the ... Republic,of China has issued the initial order to Sinovac ... to the initial order, Sinovac is,required to complete the ...
... September 4 Karolinska Development (publ),today announced that one ... clinical study of its candidate drug, tafoxiparin, a,new drug ... promising results of the Phase II trial bring the ... strategy. , Dilafor,s candidate drug, ...
Cached Biology Technology:263 Regulatory Professionals Achieve RAC Certification 2263 Regulatory Professionals Achieve RAC Certification 3Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 2Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 3Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 2Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 3
Request Info...
supplied with 10x reaction buffer...
... from yeast/leuconostoc overproducer ATP: ... EC 2.7.1.1/1.1.1.49. One unit of ... of D-glucose in 1 min ... One unit of G6P-DH will ...
Request Info...
Biology Products: